

# CENTRAL LABORATORIES

INDUSTRY LEADER IN CARDIOVASCULAR, METABOLIC & LIPID DISEASES & DISORDERS

## GLOBAL EXPERIENCE

510  
STUDIES

385K+  
SUBJECTS  
SCREENED

125K+  
SITES  
MANAGED

13K+  
VALIDATED  
ASSAYS

NEW BIOMARKERS VALIDATED IN AN INDUSTRY  
LEADING 10-12 WEEKS

## INDICATIONS

## HIGHLIGHTS

*From Discovery and Proof of Concept  
Through Large, Long Term Global Trials*

- Since 1985, Medpace central laboratory operations has been part of virtually every successful New Drug Application (NDA) involving lipid modifying therapies including, but not limited to, all “statins”, apo B antisense, and omega-3 agents.
- Provided efficacy analysis for two Proprotein convertase subtilisin/kexin type 9 (PCSK9) mAb inhibitors that supported acceptance of the FDA biologics license application (BLA), European & Global filing, and subsequent approvals by the FDA and EMEA.
- Supported Phase I – IV trials involving numerous lipid altering mechanisms including Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition involving monoclonal antibodies, RNA interference, and fusion proteins, cholesterylester transfer protein (CETP) inhibition, Diacylglycerol Transferase (DGAT-1) inhibition, peroxisome proliferator-activated receptor (PPAR) agonism, omega-3 fatty acids, niacin analogs, and modifications of other biomarkers known to affect lipid metabolism such as Apo CIII and ANGPTL3 (angiopoietin-like 3).

### CARDIOVASCULAR DISEASES

- Acute coronary symptoms
- Arrhythmias
- ASCVD
- Dilated cardiomyopathy
- Heart failure
- Peripheral arterial disease
- Stroke
- Thromboembolic diseases

### METABOLIC DISORDERS

- Acromegaly
- Acute intermittent porphyria
- Adrenal disorders
- Cushing's syndrome
- Diabetes mellitus type I
- Diabetes mellitus type II
- Electrolyte disturbances
- Hereditary angioedema
- Hypertension
- NAFLD
- NASH
- Wilson's disease


### LIPID DISORDERS

- Familial chylomicronemia syndrome
- Heterozygous familial hypercholesterolemia
- Homozygous familial hypercholesterolemia
- Hyperlipoproteinemia (a)
- Hypertriglyceridemia
- Hypoalphalipoproteinemia
- Lecithin cholesterol acyltransferase deficiency
- Lipid storage diseases
- Lipodystrophy
- Lipoprotein lipase deficiency
- Mixed dyslipidemia
- Primary hypercholesterolemia

MEDPACE

# BIOANALYTICAL LAB

PROVIDING ACCURATE, HIGH-QUALITY RESULTS IN A TIMELY, SECURE, AND COST-EFFECTIVE MANNER



- PK Assays
- Chiral Molecules
- ICP-MS
- GC-MS
- Metabolite ID
- Biomarkers

- PK Assays
- ADA Assays
- NAB Assays
- ANA Assays
- PCR Assays
- Flow Cytometry
- Biomarkers

- Method Development, Feasibility, and Validation
- Pre-Clinical and Clinical Sample Analysis
- Analytical Support For:
  - Clinical PK and ADA Studies
  - Non-Clinical TK Studies
  - Bioequivalence, Bioavailability, Dose Escalating Studies
- Pharmacodynamics/Biomarker Studies

## MEDPACE LABS STAND OUT

*Experienced and Highly-Trained Scientists  
Supported by Expert Staff*

### What's The Difference?

### Advantage

- |   |  |
|---|--|
| Experience with small and large molecule biomarkers | Diverse experience to expedite research                                |
| Expert leaders with years of experience             | Anticipates problems and prepares solutions                            |
| Fully-integrated with Medpace CRO                   | Delivers efficient and streamlined execution with high quality results |
| Good Laboratory Practice (GLP) compliant            | Ensures the highest quality testing and results                        |
| State-of-the-art equipment and instrumentation      | Advanced knowledge of necessary instruments                            |
| Quality assurance present on site                   | Streamlines communication of all data                                  |
| Local storage units with large capacity             | Stores all study samples in one centralized location                   |

## MULTI-PHASE SUPPORT

*A Partner Throughout Drug Development*

